Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRND | Q07001 | 6/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.44 |
| ▸ | CHRNG | P07510 | 2/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24496495 | 0.95 | TRPV1 (0.45) | CHRNDTRPV1NPY1RNPY2RNPY4R | |
| SCHEMBL22702533 | 0.94 | NPY5R (0.47) | TRPV1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL22336348 | 0.94 | TRPV1 (0.44) | TRPV1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL22336351 | 0.94 | TRPV1 (0.44) | TRPV1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL19591557 | 0.93 | FURIN (0.49) | CHRNDCHRNA1CHRNGCHRNB1GRIA1 | |
| SCHEMBL22746602 | 0.92 | TRPV1 (0.42) | TRPV1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL24270749 | 0.92 | FURIN (0.43) | CHRNDCHRNA1CHRNGCHRNB1GRIA1 | |
| SCHEMBL25826708 | 0.91 | NPY4R (0.47) | TRPV1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL21754508 | 0.91 | NPY4R (0.47) | TRPV1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL24029087 | 0.91 | TRPV1 (0.43) | TRPV1NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
| US-20210283267-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | VOR BIOPHARMA, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283267-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | CD44, FCGR1A, FCGR3B | CHRND 2747/4885CHRNA1 2364/4885CHRNG 896/4885 |
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | CD59, CD58, CD2 | CHRND 843/4885CHRNA1 748/4885CHRNG 533/4885 |
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | CD2, CD4, CD22 | CHRND 301/4885CHRNA1 1418/4885CHRNG 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.